Biotech Values

[DewDiligence]

ASMB inks drug-development collaboration with AGN—but shares fall:

http://finance.yahoo.com/news/allergan-enters-licensing-agreement-assembly-130000565.html

Under the terms of the agreement, Allergan will make an upfront payment to Assembly of $50 million for the exclusive, worldwide rights to develop and commercialize the UC, CD and IBS compounds. Additionally, Assembly will be entitled to receive success-based development and commercial milestone payments. Assembly is also eligible to receive tiered royalties based on net sales. Allergan and Assembly will generally share development costs through proof-of-concept (POC) studies, and Allergan will assume all post-POC development costs.